drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An IgG1 bispecific antibody that binds CD3 on T cells and BCMA (TNFRSF17) on malignant plasma cells, redirecting T cells to BCMA-expressing myeloma cells to trigger TCR/CD3 signaling, immune synapse formation, and T-cell–mediated cytotoxicity (perforin/granzyme release and cytokine secretion). Administered intravenously with dose escalation.
nci_thesaurus_concept_id
C199313
nci_thesaurus_definition
A T-cell engaging, human, bispecific, immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD3/anti-BCMA bispecific antibody TQB2934 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
IgG1 bispecific antibody that binds CD3 on T cells and BCMA (TNFRSF17) on malignant plasma cells, bringing T cells into proximity with BCMA+ myeloma cells to trigger TCR/CD3 signaling, immune synapse formation, and T-cell–mediated cytotoxicity (perforin/granzyme release and cytokine secretion), resulting in lysis of BCMA-expressing tumor cells.
drug_name
TQB2934
nct_id_drug_ref
NCT05646758